The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Clinical, pathologic, genomic and immunophenotypic characterization of KRAS G12V NSCLC
Hui Jing Hoe, MBBS, Dana-Farber Cancer Institute, Boston, MA, shares insights into a study characterizing the clinical, pathologic, genomic and immunophenotypic features of KRAS G12V non-small cell lung cancer (NSCLC). Similar features were found between KRAS G12V and G12C tumors, with common adenocarcinoma histology and the immune profile identified was comparable to G12C tumors with similar immune activity. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
